Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

[No opiates against cannabis hyperemesis syndrome].

Bonnet U, Stratmann U, Isbruch K.

Dtsch Med Wochenschr. 2014 Feb;139(8):375-7. doi: 10.1055/s-0033-1360065. Epub 2014 Feb 11. German.

PMID:
24519114
2.

Haloperidol for treatment of cannabinoid hyperemesis syndrome.

Hickey JL, Witsil JC, Mycyk MB.

Am J Emerg Med. 2013 Jun;31(6):1003.e5-6. doi: 10.1016/j.ajem.2013.02.021. Epub 2013 Apr 10.

PMID:
23583118
3.

[Cannabis hyperemesis syndrome].

Bonnet U, Chang DI, Scherbaum N.

Fortschr Neurol Psychiatr. 2012 Feb;80(2):98-101. doi: 10.1055/s-0031-1273372. Epub 2011 Jun 20. German.

PMID:
21692016
4.

Is haloperidol the wonder drug for cannabinoid hyperemesis syndrome?

Inayat F, Virk HU, Ullah W, Hussain Q.

BMJ Case Rep. 2017 Jan 4;2017. pii: bcr2016218239. doi: 10.1136/bcr-2016-218239.

PMID:
28052951
5.

[Cannabis withdrawal syndrome in patients with cannabis dependence only, and in patients with cannabis and opioid dependence].

Vorspan F, Guillem E, Bloch V, Bellais L, Sicot R, Noble F, Lepine JP, Gorelick DA.

Encephale. 2011 Sep;37(4):266-72. doi: 10.1016/j.encep.2010.12.007. Epub 2011 Feb 5. French.

PMID:
21981886
6.

Use of dronabinol for cannabis dependence: two case reports and review.

Levin FR, Kleber HD.

Am J Addict. 2008 Mar-Apr;17(2):161-4. doi: 10.1080/10550490701861177. Review.

7.

Cannabinoid hyperemesis syndrome: a guide for the practising clinician.

Bajgoric S, Samra K, Chandrapalan S, Gautam N.

BMJ Case Rep. 2015 Dec 23;2015. pii: bcr2015210246. doi: 10.1136/bcr-2015-210246. Review.

PMID:
26698198
8.

Acetyl-L-carnitine in the management of pain during methadone withdrawal syndrome.

Janiri L, Martinotti G, Tonioni F, Ghelardini C, Nicolai R, Galeotti N, Mosconi L, Calvani M, Bartolini A, Iannoni E.

Clin Neuropharmacol. 2009 Jan-Feb;32(1):35-40. doi: 10.1097/WNF.0B013E31815DD465.

PMID:
18978503
9.

Slow-release oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with inadequate withdrawal suppression.

Kastelic A, Dubajic G, Strbad E.

Addiction. 2008 Nov;103(11):1837-46. doi: 10.1111/j.1360-0443.2008.02334.x.

PMID:
19032534
10.

Methadone combined with clonidine versus clonidine alone in opiate detoxification.

Wilson RS, DiGeorge WS.

J Subst Abuse Treat. 1993 Nov-Dec;10(6):529-35.

PMID:
8308937
11.

Cannabinoid hyperemesis syndrome.

Parekh JD, Wozniak SE, Khan K, Dutta SK.

BMJ Case Rep. 2016 Jan 20;2016. pii: bcr2015213620. doi: 10.1136/bcr-2015-213620.

PMID:
26791124
12.

A double-blind, randomized, parallel group study to compare the efficacy, safety and tolerability of slow-release oral morphine versus methadone in opioid-dependent in-patients willing to undergo detoxification.

Madlung-Kratzer E, Spitzer B, Brosch R, Dunkel D, Haring C.

Addiction. 2009 Sep;104(9):1549-57. doi: 10.1111/j.1360-0443.2009.02653.x. Erratum in: Addiction. 2009 Nov;104(11):1947. Spitzer, Berhard [corrected to Spitzer, Bernhard].

13.

[Cannabinoid hyperemesis with the unusual symptom of compulsive bathing].

Boeckxstaens GE.

Ned Tijdschr Geneeskd. 2005 Jun 25;149(26):1468-71. Dutch.

PMID:
16010960
14.
15.
16.

Combined naloxone/methadone preparations for opiate substitution therapy.

Loimer N, Presslich O, Gr├╝nberger J, Linzmayer L.

J Subst Abuse Treat. 1991;8(3):157-60.

PMID:
1960767
17.

Effects of chronic, heavy cannabis use on executive functions.

Crean RD, Tapert SF, Minassian A, Macdonald K, Crane NA, Mason BJ.

J Addict Med. 2011 Mar;5(1):9-15. doi: 10.1097/ADM.0b013e31820cdd57.

18.

No evidence for reduction of opioid-withdrawal symptoms by cannabis smoking during a methadone dose taper.

Epstein DH, Preston KL.

Am J Addict. 2015 Jun;24(4):323-8. doi: 10.1111/ajad.12183. Epub 2015 Apr 6.

PMID:
25846329
19.

[Cannabinoid hyperemesis syndrome].

Stuijvenberg MP, Ramaekers GM, Bijpost Y.

Ned Tijdschr Geneeskd. 2011;155:A2880. Dutch.

PMID:
21426598
20.

Medical mismanagement in public methadone programs.

Blansfield HN.

Conn Med. 1994 Mar;58(3):161-4. No abstract available.

PMID:
8039380

Supplemental Content

Support Center